Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-06
2009-06-02
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000
Reexamination Certificate
active
07541362
ABSTRACT:
Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 3097209 (1963-07-01), Janssen
patent: 3406199 (1968-10-01), Weber et al.
patent: 4298734 (1981-11-01), Temple, Jr.
patent: 4472398 (1984-09-01), Meszaros et al.
patent: 4611004 (1986-09-01), Ackermann et al.
patent: 4755594 (1988-07-01), Bridges et al.
patent: 4918074 (1990-04-01), Tsuda et al.
patent: 5281625 (1994-01-01), Zipplies et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5631282 (1997-05-01), Goetz
patent: 5646162 (1997-07-01), Müller et al.
patent: 5670504 (1997-09-01), Bochis et al.
patent: 5679705 (1997-10-01), Baker et al.
patent: 5696156 (1997-12-01), Baker et al.
patent: 5900415 (1999-05-01), Peterson et al.
patent: 5952363 (1999-09-01), Kristiansen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6150356 (2000-11-01), Lloyd et al.
patent: 6426365 (2002-07-01), Shinkai et al.
patent: 6455550 (2002-09-01), Chen et al.
patent: 6632836 (2003-10-01), Baker et al.
patent: 6660742 (2003-12-01), Lee
patent: 6706720 (2004-03-01), Atwal et al.
patent: 6953792 (2005-10-01), Pineiro et al.
patent: 7157451 (2007-01-01), Atwal et al.
patent: 2004/0014748 (2004-01-01), Grutzmann et al.
patent: 2004/0171642 (2004-09-01), Pineiro et al.
patent: 3309432 (1983-09-01), None
patent: 163 240 (1985-12-01), None
patent: 183 848 (1986-06-01), None
patent: 217 142 (1987-04-01), None
patent: 254 119 (1988-01-01), None
patent: 304 001 (1989-02-01), None
patent: 0 565 096 (1993-10-01), None
patent: 1596320 (1981-08-01), None
patent: 59116243 (1984-07-01), None
patent: 61-227584 (1986-10-01), None
patent: 63-60985 (1988-03-01), None
patent: 63-107983 (1988-05-01), None
patent: 1-271751 (1989-10-01), None
patent: 8-301871 (1996-11-01), None
patent: WO 85/04172 (1985-09-01), None
patent: WO 90/10632 (1990-09-01), None
patent: WO 93/14083 (1993-07-01), None
patent: WO 97/35550 (1997-10-01), None
patent: WO 98/18475 (1998-05-01), None
patent: WO 98/18476 (1998-05-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 03/088908 (2003-10-01), None
Yi et al., Colloqium: Controlling potassium channel activities: Interplay between the membrane and intracellular factors, PNAS, vol. 98, No. 20, Sep. 25, 2001.
Li G-R, Feng J, Yue L, Carrier M, Nattel S. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 1996; 78:689-696.
Feng J, Wible B, Li GR, Wang Z, Nattel S. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ. Res. Apr. 1997; 80(4):572-579.
Amos GJ, Wettwer E. Metzger F, Li Q, Himmel HM, Ravens U. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol (Lond). 1996; 4911:31-50.
Cochran et al., “Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K+-channels,” Eur J Neurosci. Nov. 2001;14(9):1455-63.
Coleman et al., “Subunit composition of Kv1 channels in human CNS,” J Neurochem. Aug. 1999;73(2):849-58.
Davies et al., “Kv channel subunit expression in rat pulmonary arteries,” Lung. 2001;179(3):147-61. Epub Feb. 4, 2002.
Frey et al., “Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine,” Neurogastroenterol Motil. Dec. 2000;12(6):509-16.
Hanson et al., “UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation,” British Journal of Pharmacology (1999), 126, 1707-1716.
Hatton et al., “Functional and molecular expression of a voltage-dependent K(+) channel (Kv1.1) in interstitial cells of Cajal,” J Physiol. Jun. 1, 2001;533 (Pt 2):315-27.
Koh et al., “Contribution of delayed rectifier potassium currents to the electrical activity of murine colonic smooth muscle,” J Physiol. Mar. 1, 1999; 515 ( Pt 2):475-87.
Kourrich et al., “Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats,” Behav Brain Res. Apr. 8, 2001;120(1):35-46.
Lopantsev et al., “Hyperexcitability of CA3 pyramidal cells in mice lacking the potassium channel subunit Kv1.1,” Epilepsia. Dec. 2003;44(12):1506-12.
MacDonald et al., “Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion,” Mol Endocrinol. Aug. 2001;15(8):1423-35.
MacDonald et al., “Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets,” Diabetologia. Aug. 2003;46(8):1046-62. Epub Jun. 27, 2003.
Pozeg et al., “In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats,” Circulation. Apr. 22, 2003;107(15):2037-44. Epub Apr. 14, 2003.
Rho et al., “Developmental seizure susceptibility of kv1.1 potassium channel knockout mice,” Dev Neurosci. Nov. 1999;21(3-5):320-7.
Shah et al., “Immunosuppressive effects of a Kv1.3 inhibitor,” Cellular Immunology 221, (2003), 100-106.
Vianna-Jorge et al., “Shaker-type Kv1 channel blockers increase the peristaltic activity of guinea-pig ileum by stimulating acetylcholine and tachykinins release by the enteric nervous system,” Br J Pharmacol. Jan. 2003; 138(1):57-62.
Wickenden, “Potassium channels as anti-epileptic drug targets,” Neuropharmacology. Dec. 2002;43(7):1055-60.
Wulff et al., “Potassium channels as therapeutic targets for autoimmune disorders,” Current Opinion in Drug Discovery & Development 2003 6(5):640-647.
Xu et al., “The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity,” Proc Natl Acad Sci U S A. Mar. 2, 2004;101(9):3112-7. Epub Feb. 23, 2004.
Bremner et al., Therapy of Crohn's Disease in childhood, Expert Opin: Pharmacother 3(7), pp. 809-825, 2002.
Singh et al., Immune therapy in inflammatory bowel disease and models of colitis, British Journa of Surgery, 88, 1558-569, 2001.
Robinson, Medical Therapy of Inflammatory Bowel Disease forthe 21s˜ Century., Eur˜, !. Surg. Supp1582, p. 90-98, 1998.
Chandy and Gutman, “Voltage-gated potassium channel genes” in Handbook of Receptors and Channels—Ligand and Voltage-gated Ion Channels, ed. R.A. North, 1995.
Doupnik et al., Curr. Opin. Neurobiol. 5:268, 1995.
Chandy et al., J. Exp. Med. 160, 369, 1984.
Price et al., Proc. Natl, Acad, Sci. USA, 86, 10171, 1989.
Leonard et al., Proc. Natl, Acad. Sci, USA, 89, 10094, 1992.
Lin et al., J. exp. Med, 177, 637, 1993.
Singh B.N., Vaughan Williams E.M. “A Third Class of Anti-Arrhythmic Action: Effects On Atrial And Ventricular Intracellular Potentials And Other Pharmacological Actions On Cardiac Muscle, of MJ 1999 and AH 3747” Br. J. Pharmacol 1970; 39:675-689.
Singh B.N., Vaughan Williams E.M, “The Effect of Amiodarone, A New Anti-Anginal Drug, On Cardiac Muscle”, Br J. Pharmacol 1970; 39:657-667.
Decoursey et al., Nature, 307, 465, 1984.
Sanguinetti and Jurkiewicz, Two Components Of Cardiac Delayed Rectifier K+ Current: Differential Sensitivity To Block By Class III Antiarrhythmic Agents, J Gen Physiol 1990, 96:195-215.
Balser J.R. Bennett, P.B., Hondeghem, L.M. and Roden, D.M. Suppression Of Time-Dependent Outward Current In Guinea Pig Ventricular Myocytes: Actions Of Quinidine And Amiodarone. Circ. Res. 1991, 69:519-529.
Nademanee, K. “The Amiodarone
Atwal Karnail S.
Bhandaru Rao S.
Finlay Heather
Lloyd John
Vaccaro Wayne
Bogie Terence J.
Bristol--Myers Squibb Company
Rao Deepak
LandOfFree
Heterocyclic dihydropyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic dihydropyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic dihydropyrimidine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088137